Clinical Evaluation of P21 Activated Kinase 1 (PAK1) Activation in Gliomas and Its Effect on Cell Proliferation.


Journal

Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154

Informations de publication

Date de publication:
Jan 2021
Historique:
pubmed: 1 12 2020
medline: 14 1 2021
entrez: 30 11 2020
Statut: ppublish

Résumé

Glioblastomas are the primary malignant tumors of brain tissues with poor prognosis and highly invasive phenotypes. Till now Ki-67 LI has emerged as a well-studied proliferation marker that aids in tumor grading, but labeling index alone cannot predict overall survival in gliomas. P21 activated kinase 1 (PAK1) - a serine/threonine kinase has been shown to function as downstream nodule for various oncogenic signaling pathways that promote neoplastic changes. This study is designed to evaluate the expression of PAK1 across various grades and its correlation with Ki-67 LI and overall survival rates among a total number of 140 clinical brain tumors of glioma patients. We also studied the activation status of phospho PAK1 in glioma tissues and established the role of PAK1 in proliferation of glioblatoma cell lines under γ-irradiation.This study provides molecular evidence signifying the role of PAK1 and its activation status in the progression of Gliomas to more aggressive phenotypes.

Identifiants

pubmed: 33251876
doi: 10.1080/07357907.2020.1858097
doi:

Substances chimiques

PAK1 protein, human EC 2.7.11.1
p21-Activated Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-113

Auteurs

Akkanapally Venu (A)

Department of Human Genetics, Sri Ramachandra Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Balasubramanian Archana (B)

Department of Pathology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Rahul Kanumuri (R)

Department of Human Genetics, Sri Ramachandra Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Veena Kumari Vuttaradhi (VK)

Department of Biotechnology, Indian Institute of Technology, Chennai, India.

Lawrence D'Cruze (L)

Department of Pathology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Sowmiya Murugan (S)

Department of Pathology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Krishnamurthy Ganesh (K)

Department of Neurosurgery, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Duvuru Prathiba (D)

Department of Biotechnology, Indian Institute of Technology, Chennai, India.

Mayya Alexandrovna Dymova (MA)

Institute of Chemical Biology and Fundamental Medicine of Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.

Suresh Kumar Rayala (SK)

Department of Pathology, Sri Ramachandra Medical College, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Ganesh Venkatraman (G)

Department of Human Genetics, Sri Ramachandra Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH